Highline Capital Management LLC Stake in Biomarin Pharmaceutical INC (BMRN) Raised by $4.28 Million as Stock Value Rose

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) LogoInvestors sentiment increased to 1.21 in 2018 Q2. Its up 0.25, from 0.96 in 2018Q1. It increased, as 30 investors sold BMRN shares while 118 reduced holdings. 57 funds opened positions while 122 raised stakes. 177.65 million shares or 1.83% more from 174.46 million shares in 2018Q1 were reported. Clarivest Asset Mgmt Ltd accumulated 3 shares. Amp Investors holds 107,138 shares. Gradient Invs Ltd Limited Liability Company holds 0% or 300 shares in its portfolio. Public Employees Retirement Association Of Colorado owns 0.02% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 32,788 shares. Neuberger Berman Grp Ltd Liability Company invested in 0.12% or 1.19 million shares. Peak6 LP reported 0.04% stake. Suntrust Banks has 0.01% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 10,514 shares. State Of Wisconsin Board holds 0.04% or 162,309 shares. Rhenman And Prns Asset Mgmt reported 239,849 shares. First Personal Finance invested 0.01% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Appleton Prns Incorporated Ma has invested 0.06% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Synovus Corporation, Georgia-based fund reported 31,378 shares. Northwestern Mutual Wealth Mgmt invested in 1,051 shares. Plante Moran Advsrs Ltd Company accumulated 0% or 25 shares. Deutsche State Bank Ag holds 0.06% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 984,234 shares.

Since June 11, 2018, it had 0 buys, and 22 insider sales for $12.94 million activity. Davis George Eric also sold $220,386 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Friday, September 14. The insider BIENAIME JEAN JACQUES sold $149,040. Another trade for 31,000 shares valued at $2.79 million was sold by FUCHS HENRY J. On Wednesday, September 5 the insider HERON ELAINE J sold $96,935. Mueller Brian sold $312,928 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Friday, June 22. LAWLIS V BRYAN sold $201,068 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Wednesday, June 27.

Highline Capital Management Llc increased its stake in Biomarin Pharmaceutical Inc (BMRN) by 3.58% based on its latest 2018Q2 regulatory filing with the SEC. Highline Capital Management Llc bought 45,550 shares as the company’s stock rose 10.80% with the market. The hedge fund held 1.32 million shares of the major pharmaceuticals company at the end of 2018Q2, valued at $124.29M, up from 1.27M at the end of the previous reported quarter. Highline Capital Management Llc who had been investing in Biomarin Pharmaceutical Inc for a number of months, seems to be bullish on the $16.51B market cap company. The stock decreased 2.97% or $2.84 during the last trading session, reaching $92.7. About 713,773 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has risen 7.26% since December 8, 2017 and is uptrending. It has underperformed by 8.36% the S&P500.

Highline Capital Management Llc, which manages about $3.04 billion and $2.99B US Long portfolio, decreased its stake in Vici Pptys Inc by 399,585 shares to 3.48 million shares, valued at $70.36M in 2018Q2, according to the filing. It also reduced its holding in Liberty Global Plc (NASDAQ:LBTYK) by 1.50 million shares in the quarter, leaving it with 3.72 million shares, and cut its stake in Gci Liberty Inc.

More notable recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: Nasdaq.com which released: “BioMarin Pharmaceutical (BMRN) Down 3.1% Since Earnings Report: Can It Rebound? – Nasdaq” on March 26, 2018, also Benzinga.com with their article: “Abbott Laboratories (NYSE:ABT), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – 3 Screens That Hint At Which Stocks May Outperform In Q4 – Benzinga” published on October 05, 2018, Streetinsider.com published: “BioMarin sets stage early for hemophilia cure off-Broadway – StreetInsider.com” on November 21, 2018. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were released by: Nasdaq.com and their article: “BioMarin (BMRN) to Report Q2 Earnings: What’s in the Cards? – Nasdaq” published on July 30, 2018 as well as Nasdaq.com‘s news article titled: “Catalysts That Could Move Catalyst Pharma – Nasdaq” with publication date: November 28, 2018.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Among 9 analysts covering BioMarin (NASDAQ:BMRN), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. BioMarin had 12 analyst reports since June 15, 2018 according to SRatingsIntel. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Buy” rating by Wedbush on Friday, June 15. The company was maintained on Friday, August 3 by Morgan Stanley. The company was maintained on Friday, August 3 by Stifel Nicolaus. The firm has “Outperform” rating given on Monday, August 6 by Wedbush. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Equal-Weight” rating by Barclays Capital on Monday, August 6. The firm has “Buy” rating by Canaccord Genuity given on Tuesday, October 23. Citigroup maintained the shares of BMRN in report on Thursday, August 9 with “Buy” rating. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Outperform” rating given on Friday, October 26 by Raymond James. Canaccord Genuity maintained the stock with “Buy” rating in Tuesday, July 31 report. The firm has “Outperform” rating by Credit Suisse given on Monday, July 9.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.